Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Insider Sells 162 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 162 shares of the company’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $78.03, for a total transaction of $12,640.86. Following the completion of the sale, the insider now directly owns 17,447 shares in the company, valued at approximately $1,361,389.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shannon Thyme Klinger also recently made the following trade(s):

• On Monday, June 10th, Shannon Thyme Klinger sold 5,178 shares of Moderna stock. The shares were sold at an average price of $148.09, for a total value of $766,810.02.

Moderna Stock Performance

NASDAQ:MRNA opened at $77.40 on Monday. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The firm’s 50 day moving average is $104.62 and its two-hundred day moving average is $113.18. The company has a market cap of $29.75 billion, a P/E ratio of -4.94 and a beta of 1.67. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period last year, the company posted ($3.62) EPS. The business’s quarterly revenue was down 29.9% on a year-over-year basis. Analysts expect that Moderna, Inc. will post -9.52 EPS for the current year.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after buying an additional 5,129,800 shares during the period. Wellington Management Group LLP increased its position in shares of Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after acquiring an additional 1,614,460 shares in the last quarter. Capital World Investors raised its stake in shares of Moderna by 0.5% in the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after acquiring an additional 18,728 shares during the period. Norges Bank purchased a new position in shares of Moderna in the 4th quarter valued at $347,565,000. Finally, Mawer Investment Management Ltd. lifted its holdings in shares of Moderna by 6.7% during the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after acquiring an additional 120,621 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MRNA has been the subject of a number of analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Thursday, August 1st. The Goldman Sachs Group cut their target price on shares of Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Oppenheimer raised their price target on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 12th. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research report on Wednesday, August 28th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Moderna from $96.00 to $88.00 and set a “neutral” rating on the stock in a research note on Thursday, August 15th. Ten equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $123.79.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.